Cardiovascular risk

Assessing cardiovascular risk

Optimal cardiovascular risk assessment allows doctors to adjust treatment in high-risk patients at an early stage.

Improve your cardiovascular risk assessment

Currently cardiovascular risk management is mainly based on a review of traditional risk factors such as blood pressure, lipid levels (cholesterol), HbA1c and family history.
 
High blood pressure or hypertension is an important risk factor for cardiovascular disease. An increased blood pressure leads the heart to work harder, which makes the heart and arteries more susceptible to injury. There are a number of anti-hypertensive drugs available to lower the blood pressure.
 
Lipids include cholesterol, cholesterol esters, phospholipids, and triglycerides. High levels of triglycerides and LDL cholesterol in combination with low levels of HDL cholesterol are associated with atherosclerosis (the buildup of fatty deposits in artery walls that increases the risk for heart attack and stroke). Hyperlidemia treatment can include a drug-class called ‘statins’.
 
Assessing the cardiovascular risk of a patient typically uses these traditional risk factors. Although these risk factors are very important determinants of cardiovascular risk, they do not always explain the increased cardiovascular risk in diabetes and renal failure patients.

Risk scores for cardiovascular events

Clinical guidelines in most countries prescribe physicians to use cardiovascular risk scores such as Framingham, UKPDS risk engine and SCORE. These risk scores use multiple clinical measurements (blood tests) and calculate the cardiovascular risk of patient based on that. In daily practice these risk scores are rarely used by physicians because it requires a number of time consuming and expensive laboratory tests and the clinical performance is moderate. Find out more about how the AGE Reader adds clinical information to UKPDS.

Improving cardiovascular risk assessment

Image of the AGE Reader mu

The extensively validated AGE Reader provides an immediate and non-invasive cardiovascular risk prediction. The AGE Reader is a very easy to use measurement system and as a result, leads to clinically valuable extra information.

The AGE Reader dramatically therefore improves the cardiovascular risk prediction for diabetes, renal failure, and atherosclerosis patients. In addition, the method is convenient, easy to use and validated.

Learn more about the AGE Reader

More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader mu
Non-invasive cardiovascular risk assessment
The AGE Reader mu is the next generation AGE Reader that combines a high measurement quality standard with an innovative design, at a reduced price level. The AGE Reader mu is a perfect tool for diabetologists and family doctors.
Read more »
About the company

More information about Diagnoptics.

Information for patients

Information on Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.